2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)

The markets picked Merck as the winner based on its data lung cancer. Merck’s stock was up about 3% on Monday while BMS was down about 5%.

Powered by WPeMatico